COMMUNIQUÉS West-GlobeNewswire

PROCESSA PHARMACEUTICALS, INC. ANNOUNCES ACQUISITION OF VIDYA THERAPEUTICS, INC. AND APPROXIMATELY $200 MILLION CONCURRENT PRIVATE PLACEMENT TO ADVANCE BTK INHIBITOR, VT-7208, IN MULTIPLE DISEASE AREAS
29/07/2026
Acquisition brings into Processa’s pipeline Vidya’s lead asset, VT-7208, a next-generation, CNS-penetrant, once-daily, oral potentially best-in-class Bruton’s tyrosine kinase inhibitor (BTKi) designed to overcome the [...]
TG Therapeutics to Host Conference Call on Second Quarter 2026 Financial Results and Business Update
29/07/2026
Conference Call to be Held Monday, August 3, 2026, at 8:30 am ET NEW YORK, July 29, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Monday, August 3, [...]
ADMA Biologics to Report Second Quarter 2026 Financial Results on August 5, 2026
29/07/2026
Conference Call Scheduled for August 5, 2026, at 4:30 p.m. ET RAMSEY, N.J. and BOCA RATON, Fla., July 29, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S. based, end-to-end [...]
MannKind Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPF
29/07/2026
Generally well-tolerated with no serious adverse events, bronchospasm or diarrhea; no study drug discontinuations 90% of patients had no [60%] or mild [30%] cough ~450 total inhalations administered in patients with IPF [...]
Tasrif Pharmaceutical Announces Grant of Second U.S. Patent for Humanized Monoclonal Antibodies Against the Poliovirus Receptor (CD155)
29/07/2026
TSRF-786C demonstrates sub-nanomolar affinity, a favorable in vitro safety and immunogenicity profile, and broad potential across ADCs, bispecifics, and cell therapies NEW YORK, July 29, 2026 (GLOBE NEWSWIRE) -- Tasrif [...]
Anika Reports Second Quarter 2026 Financial Results
29/07/2026
Commercial Channel Revenue Increased 17% to a Record $13.9 Million Delivered $3.3 Million of Net Income, 65% Gross Margin, and $7.1 Million of Adjusted EBITDA, Highest Since 2020 Raising Full-Year 2026 Financial [...]
Amarin Reports 2026 Second Quarter Financial Results Demonstrating Early Success of Fully Partnered International Commercial Strategy and Continued Leading U.S. Market Presence
29/07/2026
Q2 2026 Results Highlight Global Volume Growth, Lower Operating Expenses and Positive Cash Flow For Full Year 2026, Company Expects Continued Growth in International Markets, Maintenance of VASCEPA ’s U.S. Market Share [...]
Bioxytran Announces Publication of Corporate Research Report by Globe Small Cap Research
29/07/2026
Report discusses ProLectin-M Phase 2 clinical results, planned 408-patient registrational trial, the BXT-25 oxygen-therapeutic platform, and Bioxytran’s A-SUQAR commercial distribution agreement BOSTON, MASSACHUSETTS, [...]
Option Care Health Announces Financial Results For The Second Quarter Ended June 30, 2026
29/07/2026
BANNOCKBURN, Ill., July 29, 2026 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (the “Company” or “Option Care Health”) (Nasdaq: OPCH), the nation’s largest independent provider of home and alternate site infusion [...]
Alira Health Establishes Annabel de Maria Memorial Scholarship to Inspire the Next Generation of Healthcare Leaders
29/07/2026
Annual scholarship continues the vision of Alira Health's late Chief Patient Officer by supporting future leaders committed to improving healthcare and patient outcomes BARCELONA, Spain, July 29, 2026 (GLOBE NEWSWIRE [...]
Hopstem Receives U.S. FDA IND Clearance and Fast Track designations for hNPC01 in Hemorrhagic Stroke and Traumatic Brain Injury-Expanding Clinical Development Across Three Major Brain Injury Indications
29/07/2026
HOUSTON, July 29, 2026 (GLOBE NEWSWIRE) -- Hopstem Biotechnology announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application and Fast Track designations for [...]
Basilea receives USD 30 million funding under existing BARDA agreement for advancing phase 3 development of novel antifungal fosmanogepix
29/07/2026
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, July 29, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients [...]
Ceribell to Participate in the Canaccord Genuity 46th Annual Growth Conference
28/07/2026
SUNNYVALE, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological [...]
Jushi Holdings Inc. Reports Second Quarter 2026 Financial Results
28/07/2026
Revenue Increased 10% Year-over-Year to $71.3 million , Reflecting Growth Across Both Retail and Wholesale Channels Wholesale Revenue Increased 68% to an All-Time Quarterly Record of $9.4 Million Record Quarterly [...]
Healthcare Executives Signal Growing Strategic Value of Laboratory Services, Siemens Healthineers Survey Finds
28/07/2026
New research indicates attention on laboratory modernization. As the Association for Diagnostics and Laboratory Medicine 2026 Annual Scientific Meeting and Clinical Lab Expo kicks off, Siemens Healthineers will unveil [...]
National Center for Cannabis Research and Education at the University of Mississippi and Southern Sky Brands Launch CBD Sleep Study
28/07/2026
OXFORD, Miss. and CANTON, Miss., July 28, 2026 (GLOBE NEWSWIRE) -- The National Center for Cannabis Research and Education (NCCRE) at the University of Mississippi and Southern Sky Brands have announced a collaborative [...]
MannKind to Report Second Quarter Financial Results and Host Conference Call on August 5, 2026
28/07/2026
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , today announced that the Company will report second quarter 2026 financial results after market close [...]
vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
28/07/2026
HIGH POINT, N.C., July 28, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin , a novel, potential first-in-class oral [...]
Kymera Therapeutics to Report Second Quarter 2026 Financial Results on August 5, 2026
28/07/2026
WATERTOWN, Mass., July 28, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological [...]

Pages